Eiger BioPharmaceuticals, Inc.
Buffered formulations of exendin (9-39)
Last updated:
Abstract:
Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.
Status:
Grant
Type:
Utility
Filling date:
21 Nov 2017
Issue date:
1 Jun 2021